Actively Recruiting
Study of Alpelisib to Assess Safety and Effectiveness in Children and Adults With PIK3CA-Related Lymphatic Malformations
Led by Novartis Pharmaceuticals · Updated on 2026-10-09
232
Participants Needed
61
Research Sites
256 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of alpelisib film-coated tablets compared to placebo in people of all ages with lymphatic malformations caused by a PIK3CA mutation. This Phase IIIII study aims to understand changes in radiological response and symptom severity through a two-stage design, including both pediatric and adult participants. The study is sponsored by Novartis Pharmaceuticals and includes detailed safety and efficacy assessments. The study has two main stages. Stage 1 involves a 24-week open-label phase where adults 18 years and older and children aged 6-17 receive different doses of alpelisib to determine the best dose for the next phase. Stage 2 includes a 24-week randomized, double-blind, placebo-controlled phase for participants aged 6 and older, plus an open-label phase for children aged 0-5 years. Depending on Stage 1 results, specific doses will be selected for Stage 2. Extensions follow both stages to continue monitoring. Participants undergo screening to confirm eligibility, including diagnosis and genetic testing for PIK3CA mutations. Throughout the study, imaging assessments measure changes in lymphatic malformations, and symptom severity is tracked using patient and investigator scales. Safety is continuously monitored by an independent committee. The study may last several years, with follow-up assessments extending up to approximately 8 years to evaluate long-term responses and safety.
CONDITIONS
Brief Title
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here